Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NEOGAP Therapeutics

Explore full profile

Imagine if cancer patients who lack efficient treatment options could be cured

Stockholm, SwedenFounded 2016Biotech & Life Sciences
Valuation $25–50M Last recorded · 2026
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for NEOGAP Therapeutics and the history behind them.

About NEOGAP Therapeutics

Developer of personalized cancer immunotherapy designed to precisely target and eliminate cancer. The company's product identifies optimal neoantigens to target, activate and multiply T-lymphocytes with the purpose of eradicating cancer, enabling cancer patients to recover from the disease. Keywords: Pharmaceuticals and Biotechnology, Biopharmaceutical Producer, Biopharmaceutical Research, Cancer Cure Therapy, Immune System, Immuno-Oncology Drugs, Immunotherapy Drugs, Pharmaceutical, Pharmaceutical Medicine.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
Stockholm, Sweden
Employees
26
Open positions
None listed
Dealroom signal
60.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, EIC, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Investment activity
1 company, latest Jun 2023
Capital deployed
—
Preferred round
ACQUISITION
Links
WebsiteLinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Feb 2026 $11M $42M Sciety ↗
GRANTOther financing Mar 2024 $605K — Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

NEOGAP Therapeutics website traffic

Latest recorded traffic for NEOGAP Therapeutics is 590 monthly website visits, up 293.3% over the last three months. NEOGAP Therapeutics's team grew 0% over the past year.

Latest monthly visits590 3-month web change+293.3% 1-year team growth0%
Monthly website visitsMay 2023–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Celeris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases Graz, Austria Operational 1 $7.8M $17M
PaloBiofarmaA company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation Noáin (Valle de Elorz)/Noain (Elortzibar), Spain Operational
HEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy | A single platform for defeating cancer and much more Orsay, France Operational
PeptomycFoundational anti-MYC mini-proteins for cancer treatment Barcelona, Spain Operational
Arctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics Reykjavík, Iceland Operational
AtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance L'Hospitalet de Llobregat, Spain Operational
PROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables Cologne, Germany Operational
PhilogenDevelop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders Sovicille, Italy Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

TCER ABStockholms kommun, SwedenClinical stage biopharmaceutical company with the main focus on immuno-oncology
1 profiles shownExplore the complete relationship graph →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • European Innovation Council

Series A1 investor entered at this stage

  • Sciety

Talent

Book a demo to see the people
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇸🇪 Sweden100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NEOGAP Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NEOGAP Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.